Health Product Advertising Rules in Singapore: What You Can and Cannot Claim

Last updated 6 September 2026 — by Adrian Tan, SDM. Marketing guidance, not legal advice. Verify any borderline claim with HSA or your own counsel before it runs.

Here is a sentence that has killed more Singapore health campaigns than any creative review: “we cannot say that, it is not in the registration.”

It always arrives late — concept signed off, shoot booked, media budget committed — and marketers read it as a compliance department being difficult. It is not. It is black-letter Singapore law.

The confusion has one root cause. Singapore does not have a single health advertising rulebook. It has four, and which one binds you is decided by a table in a schedule to an Act — not by how medical your product sounds. A multivitamin, a knee brace, a serum and a cough syrup fall under four different instruments, with four different answers to the only two questions a marketer cares about: do I need permission before this runs, and what may I say? This guide answers both from the primary legislation.

Step one: find which box your product sits in

The First Schedule to the Health Products Act 2007 lists what counts as a “health product”. The categories that matter commercially are medical devices, cosmetic products and therapeutic products (medicines).

The most useful fact about that Schedule is what is missing. Search the entire Act and the phrase “health supplement” does not appear once. Supplements are not health products. Neither are traditional, Chinese proprietary or homoeopathic medicines, medicated oils and balms, nor what the Act calls “quasi‑medicinal products” — a defined term covering anti‑dandruff preparations, medicated soaps and plasters, cough and throat sweets, sunscreens, medicated beverages and toothpastes, acne preparations and, critically, “any vitamin or nutritional preparation from any natural source”. That exclusion is not a loophole; it is a doorway into an older and in some ways stricter regime.

Read that twice. The two rows that need a government permit before the advertisement runs are the two rows that sound least medical. A registered prescription cream needs no pre-approval. A multivitamin does.

The permit nobody budgets for

Under regulation 3 of the Medicines (Medical Advertisements) Regulations, “no person shall issue or cause to be issued any medical advertisement; or conduct any sales promotion, without first obtaining a permit from the licensing authority.” HSA is that authority, and its published processing time is 14 working days — roughly three calendar weeks if the copy is accepted first time.

Three provisions reshape how a performance team has to work.

Regulation 12 — the permit number goes in the creative. It must be “displayed on, or on material accompanying, the medical advertisement”. If you have wondered why Singapore pharmacy ads carry a small alphanumeric code, that is regulation 12. It belongs on the asset, not the landing page.

Regulation 13 — you may not change an approved advertisement. You “must not alter or amend the contents” of a permitted advertisement without applying to amend the permit and having that approved; the fee is $57. In plain terms, swapping a headline on a permitted multivitamin ad is a regulated act, and iterative creative testing is structurally incompatible with it.

Regulation 8 — the publisher has an independent duty. No person may print or publish a medical advertisement “unless he has first ascertained that a permit has been granted”. That reaches your media partners and, depending on the arrangement, your agency: whoever presses publish is expected to have checked.

Contravening regulation 3, 8, 12 or 13 is an offence under regulation 15: a fine of up to $5,000 or 12 months, or both.

What the permits cost

Fees are set by the Schedule to the Regulations as amended with effect from 1 July 2024. They are charged per advertisement, and a permit is valid for one year from the date granted (regulation 5).

Two consequences nobody plans for. Video costs half as much again as static, every year the creative stays in market — biasing permit-class brands towards static formats exactly as competitors move to short-form video. And renewal is not cheaper than year one.

Run the arithmetic and the strategy writes itself. Twelve static variants for a multivitamin launch is $2,664 in year one plus a three-week lead time on each, before a dollar of media. The answer is not to abandon testing but to move the testing off the advertisement: permit a few durable master creatives, then experiment on audience, placement, bid strategy and the landing page — none of which is the advertisement, and all of which usually carry more of the performance variance anyway. It also rewrites the seasonal calendar: a permit-class product cannot decide in late October to run an 11.11 campaign on fresh creative. And note the promotion limb — HSA’s guidance is that permitted sales promotions may not offer products free of charge or run prizes through lucky draws or contests, which removes the commonest mechanic in Singapore lucky draw campaigns for this product class.

The nineteen diseases: one list, three statutes

If you take one asset from this article, take this list. It appears in near-identical terms in three places: the Schedule to the Medicines (Advertisement and Sale) Act 1955, the Third Schedule to S 333/2016, and the Second Schedule to the Medical Devices Regulations. Whatever you sell, one version applies.

Blindness · Cancer · Cataract · Conception and pregnancy · Deafness · Diabetes · Drug addiction · Epilepsy or fits · Frigidity · Hypertension · Impotency · Infertility · Insanity · Kidney diseases · Leprosy · Menstrual disorders · Paralysis · Sexual function · Tuberculosis

Read it as a copywriter and the modern exposure jumps out. It is not confined to grave illness. “Menstrual disorders” catches period-cramp positioning; “conception and pregnancy” catches the whole fertility-support supplement category; “diabetes” and “hypertension” catch the very common “supports healthy blood sugar” and “supports healthy blood pressure” formulations. And item 18 is “sexual function”, not “sexual dysfunction” — so a claim to improve is caught as squarely as a claim to cure.

The wording matters as much as the list. Regulation 6(1) of S 333/2016 bars an advertisement that “expressly or implicitly” claims the product will prevent, alleviate or cure a listed condition; then bars any claim it will “prevent or alleviate any sign or symptom clinically attributable to” one; then bars any claim it “has similar properties or characteristics to, or works as well as, a product that is commonly used for the purpose of treating” one. That third limb catches comparative copy: “works like a statin, without the prescription” is prohibited even though it names no disease.

If you sell a medicine: the bans that bite

The Health Products (Advertisement of Specified Health Products) Regulations 2016 carry the most detailed content rules in the system — and there is a trap most published guidance falls into. The Second Schedule defines “specified health product” as therapeutic products and cell, tissue and gene therapy products only. These Regulations do not apply to medical devices or cosmetics. If you have read elsewhere that S 333/2016 governs device advertising, that is wrong; devices have their own Part V.

Regulation 4 lists what a medicine’s advertisement must not do. The ones that bite in commercial copy:

• 4(e) — no misleading “directly or by implication or through emphasis, contrast or omission”. Note “emphasis” and “omission”: a technically true claim can breach this through framing alone.
• 4(f) — no comparison with any named competing product. Comparative advertising is off the table.
• 4(h) and 4(i) — nothing “infallible, unfailing, magical or miraculous”, no “certain, guaranteed or a sure cure”, and no claim of no side effects.
• 4(k) — no money-back guarantees. Offering, guaranteeing or even suggesting a refund of the purchase price is prohibited. A “30-day satisfaction guarantee” badge is a compliance failure here, not a conversion tactic.
• 4(m) — not directed principally at anyone under 14.
• 4(n) — no endorsement or recommendation by any healthcare professional, or by anyone who “because of the person’s celebrity, social or professional status, is likely to encourage the use” of the product. That is a clean prohibition on doctor endorsements and on influencer and KOL marketing for medicines, and it does not turn on whether the endorsement is paid or disclosed.

Regulation 7 prohibits public advertising of prescription-only medicines outright; regulation 10 bans prizes as an inducement to purchase, bundling another health product, and free samples to the public; regulation 5 requires any claim of uniqueness, certification or award to be substantiated.

Then regulation 13, the informational statement carve-out, contains the most surprising sentence in the instrument. A statement on the registrant’s own corporate website escapes the disease restriction and the prescription-only prohibition — but only if the representations are verifiable by objective evidence and “in the case of a corporate website, no discussion board or forum relating to the specified health product is held on the corporate website“. In other words: adding a product Q&A widget, a review thread or a community forum to your own site can cost you the exemption that lets the rest of that page exist. For anyone scoping a site redesign for a pharmaceutical brand, that is a requirement, not a preference.

If you sell a medical device: your copy ceiling was set at registration

Part V of the Health Products (Medical Devices) Regulations 2010 is short and, for a marketer, brutal.

Regulation 19(a) produces the sentence this article opened with. For a device intended for direct delivery to or use by the general public, the advertisement “shall not contain any statement concerning the intended use and efficacy of the medical device, unless — (i) such statement has been verified by objective evidence; and (ii) where the medical device is a registered medical device, the objective evidence… has been furnished to the Authority at the time the application to register the medical device was made.”

Limb (ii) is the whole game. It is not enough that your claim is true and provable — the proof had to be in the registration dossier. You cannot commission a study in Q3 to justify a new Q4 claim. The ceiling on your ad copy was fixed the day a regulatory colleague submitted the application, often years before anyone on the marketing team was hired, in a document the marketing team has never seen. So, and this is the highest-leverage line in this article: before writing a word of copy for a Singapore medical device, get the registered intended purpose and the claims evidence list out of the registration file. That document, not the creative brief, is your copy deck.

• Regulation 20(3) — where you assert a certification or award, “the identity of the certifying or awarding body and the date the certification or award was granted” must be indicated on the face of the advertisement. “Award-winning” in a headline with the detail on the landing page does not satisfy that.
• Regulation 21 — “professional use only” devices may not be advertised except to qualified practitioners.
• Regulation 23 — HSA may require copies of any advertisement issued within the 12 months immediately preceding the notice. That is an archiving obligation in disguise, and dynamic creative, dark posts and expired Meta assets are exactly what is hardest to reconstruct afterwards. Export and date-stamp every asset at launch.

The parallel provision for medicines, regulation 15 of S 333/2016, carries its own penalty: failing to furnish copies on notice is punishable by a fine of up to $10,000 or six months — twice the maximum for advertising a medicine without a permit, and ten times the first-conviction fine under the 1955 Act. The record-keeping duty is enforced harder than the content rules.

If you sell a cosmetic: no registration, still regulated

Cosmetics are health products, but the third column of the First Schedule disapplies a long list of provisions to them, including section 15 and — notably — section 19(1)(b). There is no registration, so there is no registered purpose to exceed. What is not disapplied is the rest of Part 5: sections 20 and 21 apply in full. Section 20(2) sets a low bar — an advertisement is caught if it “is likely to create an erroneous impression regarding the formulation, composition, design specification, quality, safety, efficacy or uses” of the product. Before-and-after imagery, retouched results and “clinically proven” language all live under that sentence.

The two mirror-image offences

Two provisions point in opposite directions, and between them they close the gap most brands think they occupy.

Health Products Act section 19(1)(a): “A person must not advertise any product or cause any product to be advertised as a health product if that product is not a health product.” Fine up to $20,000 or 12 months, or both. This is the offence of borrowing medical status you do not have — a serum advertised with the visual language and claim structure of a therapeutic product; a supplement presented as though it were a registered medicine. It does not turn on whether the claim is true, but on representing the product as belonging to a regulated category it does not belong to.

Medicines (Advertisement and Sale) Act 1955 section 3(1) comes from the other side, and is extraordinarily wide. It prohibits taking part in the publication of any advertisement “referring to any article or articles of any description” in terms calculated to lead to their use “as a medicine, appliance or remedy for the purpose of treatment of human beings” for any of the nineteen scheduled diseases.

Any article of any description. A mattress, a massage gun, a red-light panel, a herbal tea, a bracelet, a juice — if the advertisement is calculated to lead a reader to use it as a remedy for a scheduled condition, the section is engaged. The statute attaches to the claim, not to the product. That is why “we are not a health brand, so these rules do not apply to us” is the most expensive sentence in this area.

Two more features matter. The Act’s definition of “advertisement” includes “any announcement made orally or by any means of producing or transmitting light or sound” — covering a livestream, a podcast read and a creator’s spoken claim on video. And section 6(2) reverses the burden of proof: where an advertisement is shown to have been published in terms calculated to lead to use for a scheduled disease, and it referred to the article in terms indicating it was sold or offered for sale by the person charged, then “unless the contrary is proved, it shall be presumed… that that person took part in the publication”. That is why “our affiliate wrote that, not us” is a weak defence. Penalties under the 1955 Act are small — up to $1,000 on a first conviction, $2,000 thereafter — but the fine is not the exposure.

Who is on the hook, and what HSA can do

HPA section 22 gives a defence to a person “whose business is to publish or arrange for the publication of advertisements”, who received it in the ordinary course of business, has no financial interest in the supply of the product, and did not know and had no reason to suspect the contravention. All three limbs must hold. A media agency placing a booking can plausibly get there; an agency that wrote the offending claim fails the third limb, and one on a performance fee tied to product sales has trouble with the second. MASA section 6(3)(a) is narrower still — a defence about participation, not content. The practical fix: make the permit number and the registered intended purpose mandatory fields in the campaign brief, and put regulatory sign-off before creative production rather than after. Being able to have this conversation at all is a fair proxy for competence — see our note on agency red flags in Singapore.

Marketers price this risk as a fine. The fine is rarely the problem. Section 23 of the Health Products Act lets HSA order you to stop the advertisement with immediate effect, remove advertisements already published, and publish a corrective advertisement in the manner and with the content HSA specifies — costs on you (s23(2)), and HSA may do it and bill you if you do not (s23(3)(b)). Sit with what that means commercially: paid media, in a placement and with copy chosen by the regulator, telling your market your previous claim was wrong, funded by you. There is no equivalent power in the 1955 Act. The statute with the $20,000 fine can make you buy media against yourself. The statute with the $1,000 fine cannot.

A process that survives contact with a campaign

1. Classify the product in writing. Which First Schedule box, or which non-health-product category? One line in the brief; everything else depends on it.
2. Establish whether a permit is needed, and start it first. For the permit-class products above it sits on the critical path at 14 working days. Build the timeline backwards from it.
3. Pull the claims ceiling. For a device, the registered intended purpose and the evidence furnished at registration; for a medicine, the registered indication. Circulate it before anyone writes.
4. Run the nineteen-disease check on every asset, including organic. Captions, creator scripts, livestream talking points, email subject lines, on-site FAQ answers and structured data are all publication.
5. Archive at launch. Asset, date, placement, permit number, twelve months rolling — that is the window HSA can ask about.

None of that is exotic; it is the discipline a Singapore website’s other legal obligations already demand, applied to creative. What makes health different is only that the ceiling on what you may say is external, documented, and older than the campaign.

Licensing can also decide whether a wellness business may advertise at all. Our guide to massage and spa advertising rules in Singapore covers the provision that makes advertising, or otherwise holding out, an unlicensed massage business an offence in its own right — and why the licence gate sits in front of every listing and Business Profile you would otherwise build first.

Frequently asked questions

Do I need HSA approval before running a health supplement ad in Singapore?

For most herbal or botanical supplements, no. But if the product is a vitamin or mineral preparation it is a quasi-medicinal product, and a permit under the Medicines (Medical Advertisements) Regulations is required before the advertisement runs — as it is for traditional, Chinese proprietary and homoeopathic medicines, medicated oils and balms, lozenges, medicated soaps and toothpastes, and topical antiseptics.

Can I use a doctor or an influencer to promote a health product?

Not for a medicine. Regulation 4(n) of S 333/2016 prohibits any endorsement of a therapeutic product by a healthcare professional, or by anyone whose celebrity, social or professional status is likely to encourage its use. For devices, cosmetics and supplements that regulation does not apply, but the general prohibitions on false and misleading advertising still do, and any testimonial should reflect a typical user’s experience and the product’s intended purpose.

What can HSA actually do if an advertisement breaches the rules?

Section 23 of the Health Products Act lets HSA order you to stop the advertisement immediately, remove already-published copies at your own cost, and publish a corrective advertisement in the form HSA specifies. If you do not comply, HSA can take those steps itself and recover the cost from you.

Does the disease list apply to organic social posts and creator content?

Yes. The 1955 Act expressly includes announcements made orally or by transmitting light or sound, and S 333/2016 defines “publish” to include disseminating or broadcasting “by any form of communication or in any manner”. A caption, a livestream and a paid placement are all publication.

My product is not a health product at all. Am I in the clear?

No. Section 3(1) of the Medicines (Advertisement and Sale) Act 1955 reaches “any article or articles of any description” advertised in terms calculated to lead to their use as a remedy for one of the nineteen scheduled conditions — it attaches to the claim, not the product category. Separately, section 19(1)(a) of the Health Products Act makes it an offence to advertise a non-health-product as a health product.

How long does a permit last, and can I edit the ad afterwards?

One year from the date granted. You may not alter the contents of a permitted advertisement without applying to amend the permit and having that approved; the fee is $57.

Where this leaves you

Most Singapore health marketing problems are not brands trying to get away with something. They are a team that never established, on day one, which of four rulebooks it was working under — then discovered in week six that the answer required a permit, a shorter claim, or a different creative architecture. The fix is the five steps above. Done early, compliance stops being a late-stage veto and becomes a set of constraints you design around — which, in a category where every competitor works under the same constraints, is an advantage rather than a tax.

If you are building a campaign for a supplement, device, skincare or clinic-adjacent brand and want a second pair of eyes on the claims architecture before production, our performance marketing team in Singapore does this work every week. You can see the results in our client case studies, including our work with Rooki Beauty. For how these campaigns are measured, start with our guide to performance marketing in Singapore; for the sector view, see our guides to healthcare and beauty marketing.